Dave Lashmet
Editor of Stansberry Venture Technology who researches small-cap biotech and pharmaceutical companies and presents in-depth analysis of emerging drug opportunities and monopolies.
Best podcasts with Dave Lashmet
Ranked by the Snipd community
11 snips
Feb 16, 2026 • 1h 6min
10:1 Risk/Reward: 3 Drug Monopolies Built for Massive Upside
Dave Lashmet, editor who hunts small‑cap biopharma winners, breaks down three drug monopolies built for massive upside. He highlights a GLP‑1 weight‑loss pill that doubles as diabetes therapy. He explains a fatty‑liver pill whose market is protected by liver irreplaceability. He profiles an MC4R hunger‑switch therapy that could disrupt current treatments.
